top of page
NEWS
News
Search


EVI joins new initiative to advance promising Hepatitis C vaccine: HCVIVA
An inactivated Hepatitis C vaccine showing promising results in preclinical trials moves closer to human trials, with a new project to establish and optimise production and manufacture of the vaccine.
EVI
1 hour ago2 min read
7


EVI to support GAVI's malaria learning agenda
New EVI-led project will assess the impact of enhancing seasonal malaria vaccination in Guinea and Benin. The findings could shape future...
EVI
2 days ago1 min read
97

EVI initiates a new clinical trial to protect pregnant women against malaria
EVI launched Phase II clinical trial to evaluate the R21/Matrix-M malaria vaccine (by Univ. of Oxford), in women of childbearing potential.
EVI
Apr 72 min read
88

World TB Day: advancing the fight against tuberculosis
March 24 marks World Tuberculosis Day on the anniversary of Dr. Robert Koch's groundbreaking discovery of Mycobacterium tuberculosis in 1882
EVI
Mar 244 min read
28

VACCELERATE concludes: achievements from the first Europe’s Corona Vaccine Trial Accelerator
From establishing a strong clinical trial network to accelerating vaccine research and fostering cross-border collaboration, VACCELERATE...
EVI
Feb 72 min read
57


New clinical trial investigates safety and immune response of Invaplex AR-Detox Shigella vaccineÂ
A newly published article outlines the protocol for new phase Ia/b clinical trial for the Invaplex AR-Detox  Shigella vaccine...
EVI
Feb 52 min read
68

TRANSVAC: a pillar of vaccine development in Europe for 16 years
The European vaccine development ecosystem has been strengthened over the last 16 years, thanks to the TRANSVAC project, funded by the EC.
EVI
Jan 312 min read
32


Publication of first-in-human data of malaria vaccine candidate, R21 in Matrix-M adjuvant
Phase 1 clinical trials in the UK and Burkina Faso showed that the malaria vaccine candidate, R21 adjuvanted with Matrix-M, has an...
EVI
Jan 303 min read
119

World Neglected Tropical Diseases (NTDs) Day 2025: UNITE, ACT, ELIMINATE
Neglected Tropical Diseases (NTDs) cause immense suffering and affect an estimated 1 billion people mostly in isolated and marginalised...
EVI
Jan 302 min read
78


Now is the time to accelerate the development of second-generation malaria vaccines through investment, innovation and public-private partnerships.
At the World Vaccine Congress 2024, an EVI-organised panel discussion explored the lessons learnt from licensed malaria vaccines.
EVI
Dec 17, 20244 min read
115


Chronicles from Malawi, Africa
Understanding cultural beliefs and practices around pregnancy and vaccination Our ethnographic study in Malawi—focused on understanding...
EVI
Dec 12, 20245 min read
151


EVI Team Retreat: strengthening resilience and building unity
November 2024 Last week, the EVI team gathered in Frankfurt for a retreat designed to recharge, step away from our daily routines, and...
EVI
Nov 22, 20241 min read
174


EVI showcases progress in placental malaria research at PDP IV Annual Meeting
T he European Vaccine Initiative (EVI) proudly participated in the Product Development Partnerships (PDP) IV Annual Meeting on November...
EVI
Nov 20, 20241 min read
99


Antimicrobial Awareness Week 2024 – Educate. Advocate. Act now against superbugs!
AMR is growing on a global scale and has become a top 10 health threat that affects the effectiveness of antimicrobial medicines.
EVI
Nov 17, 20244 min read
40

PhD Researchers advancing malaria vaccine research with successful dissertation defences in MMVC project
Two PhD students, Dr. Elizabeth Kibwana and Dr. Caroline Bundi, have successfully defended their dissertations under the Multi-Stage...
EVI
Nov 8, 20242 min read
112


ShigaPlexIM: SUNSHINE trial begins testing new shigellosis vaccine
The phase Ia/b trial for the InvaplexAR-Detox/dmLT vaccine started at LUMC, in Netherlands.
EVI
Oct 15, 20242 min read
95

EVI and TBVI team up with VAC4EU
European Vaccine Initiative (EVI) and the Tuberculosis Vaccine Initiative (TBVI) are proud to announce a new partnership with VAC4EU.
EVI
Oct 9, 20241 min read
91

Naobios and European Vaccine Initiative partner up to manufacture Respiratory Syncytial Virus (RSV) challenge agent
Collaboration will support Controlled Human Infection Model studies to accelerate development of effective and affordable RSV vaccines.
EVI
Oct 8, 20243 min read
87

Preserving European Antibiotics: The Need for Sustainable R&D FundingÂ
AMR Accelerator asks for long-term investments, emphasising the need to preserve the European capacity to combat drug-resistant infections.
EVI
Sep 23, 20243 min read
43

Launch of TRANSVAC Academy for Vaccine Researchers and Developers
EVI is thrilled to announce the launch of TRANSVAC Academy, a programme providing advanced expert-led training in vaccinology.
EVI
Aug 29, 20242 min read
139


EVI-led project drives progress in reducing animal testing
The European Pharmacopoeia has announced the end of the rabbit pyrogen testing.
EVI
Jul 9, 20242 min read
131


Socio-cultural study in Malawi: an insightful first week of field work
Ethnographic study aiming at understanding local perceptions of pregnancy and vaccinations.
EVI
Jun 26, 20241 min read
53


World Clinical Trials Day: honouring medical progress & innovation
EVI supports and coordinates various clinical trials that contributes to the fight against global health diseases.
EVI
May 20, 20241 min read
32


First NOSEVAC successful face-2-face Annual Meeting in Spain
The NOSEVAC project, co-funded by the European Commission and coordinated by European Vaccine Initiative (EVI), held its first annual...
EVI
Apr 29, 20243 min read
61
bottom of page